Latest period
$6.24B
YoY change
+28.8%
5Y CAGR
+17.8%
Peak year (2025)
$5.91B
Cumulative CapEx
$72.26B
CapEx history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $5.91B
CapEx growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +28.8%
CapEx history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $5.91B | +28.8% | +$1.32B | ||
| 2024 | $4.59B | +21.4% | +$808.00M | ||
| 2023 | $3.78B | +46.9% | +$1.21B | ||
| 2022 | $2.57B | +16.9% | +$371.00M | ||
| 2021 | $2.20B | -15.6% | −$406.00M | ||
| 2020 | $2.61B | +5.9% | +$146.00M | ||
| 2019 | $2.46B | +79.4% | +$1.09B | ||
| 2018 | $1.37B | -15.4% | −$249.00M | ||
| 2017 | $1.62B | -30.0% | −$694.00M | ||
| 2016 | $2.31B | -17.0% | −$474.00M | ||
| 2015 | $2.79B | +1.3% | +$36.00M | ||
| 2014 | $2.75B | +33.7% | +$694.00M | ||
| 2013 | $2.06B | -55.4% | −$2.56B | ||
| 2012 | $4.62B | +256.1% | +$3.32B | ||
| 2011 | $1.30B | -46.4% | −$1.12B | ||
| 2010 | $2.42B | -18.2% | −$537.00M | ||
| 2009 | $2.96B | -26.8% | −$1.08B | ||
| 2008 | $4.04B | +140.6% | +$2.36B | ||
| 2007 | $1.68B | +25.4% | +$340.00M | ||
| 2006 | $1.34B | +36.8% | +$360.00M | ||
| 2005 | $979.00M | +194.9% | +$647.00M | ||
| 2004 | $332.00M | -74.1% | −$950.00M | ||
| 2003 | $1.28B | -4.3% | −$58.00M | ||
| 2002 | $1.34B | -40.8% | −$922.69M | ||
| 2001 | $2.26B | +54.9% | +$801.94M | ||
| 2000 | $1.46B | -46.9% | −$1.29B | ||
| 1999 | $2.75B | +225.7% | +$1.91B | ||
| 1998 | $844.88M | +11.8% | +$89.41M | ||
| 1997 | $755.47M | +18.3% | +$116.71M | ||
| 1996 | $638.76M | +48.2% | +$207.65M | ||
| 1995 | $431.11M | -12.5% | −$61.36M | ||
| 1994 | $492.47M | +6.4% | +$29.48M | ||
| 1993 | $462.99M | +13.9% | +$56.52M | ||
| 1992 | $406.47M | +5.5% | +$21.01M | ||
| 1991 | $385.46M | -28.6% | −$154.64M | ||
| 1990 | $540.10M | — | — |
- 2025$5.91B+28.8%
- 2024$4.59B+21.4%
- 2023$3.78B+46.9%
- 2022$2.57B+16.9%
- 2021$2.20B-15.6%
- 2020$2.61B+5.9%
- 2019$2.46B+79.4%
- 2018$1.37B-15.4%
- 2017$1.62B-30.0%
- 2016$2.31B-17.0%
- 2015$2.79B+1.3%
- 2014$2.75B+33.7%
- 2013$2.06B-55.4%
- 2012$4.62B+256.1%
- 2011$1.30B-46.4%
- 2010$2.42B-18.2%
- 2009$2.96B-26.8%
- 2008$4.04B+140.6%
- 2007$1.68B+25.4%
- 2006$1.34B+36.8%
- 2005$979.00M+194.9%
- 2004$332.00M-74.1%
- 2003$1.28B-4.3%
- 2002$1.34B-40.8%
- 2001$2.26B+54.9%
- 2000$1.46B-46.9%
- 1999$2.75B+225.7%
- 1998$844.88M+11.8%
- 1997$755.47M+18.3%
- 1996$638.76M+48.2%
- 1995$431.11M-12.5%
- 1994$492.47M+6.4%
- 1993$462.99M+13.9%
- 1992$406.47M+5.5%
- 1991$385.46M-28.6%
- 1990$540.10M—
CapEx values are taken from AstraZeneca's reported cash flow statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's current CapEx (TTM) is $6.24B. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of AstraZeneca (AZN) CapEx is $5.91B – grew 28.8% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca CapEx compounded at +17.8% per year, sustaining 4 straight years of year-over-year growth.
2025 marks the peak CapEx at $5.91B, with the historical low of $332.00M recorded in 2004.
AstraZeneca Capital Expenditures by Year
AstraZeneca Capital Expenditures 2025: $5.91B
In 2025, AstraZeneca reported CapEx of $5.91B, grew 28.8% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca Capital Expenditures 2024: $4.59B
AstraZeneca CapEx in 2024 was $4.59B, grew 21.4% from 2023.
AstraZeneca Capital Expenditures 2023: $3.78B
2023's CapEx for AstraZeneca came in at $3.78B, surged 46.9% from 2022.
AstraZeneca Capital Expenditures 2022: $2.57B
AstraZeneca posted CapEx of $2.57B in 2022, grew 16.9% from 2021.
AstraZeneca Capital Expenditures 2021: $2.20B
AstraZeneca CapEx in 2021 was $2.20B.
See more financial history for AstraZeneca (AZN).
Sector peers by CapEx
Healthcare peers of AstraZeneca (AZN), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $1.86B | |
| $1.52B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $1.86B
- $1.21B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation